New pill could take the edge off social anxiety on the spot

NCT ID NCT06510504

Completed Symptom relief Sponsor: Bionomics Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single dose of BNC210 can quickly reduce anxiety in people with social anxiety disorder. 370 adults took either the drug or a placebo before a public speaking challenge and rated their distress. The goal is to see if BNC210 works as an as-needed treatment for social anxiety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BNC210
What this could lead to: If successful, BNC210 could offer a fast-acting, on-demand option to ease anxiety during social situations like public speaking.
What could go wrong: This is a completed Phase 3 trial, but results are not yet public. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOCIAL ANXIETY DISORDER

Contacts and locations

Locations

AFFIRM-1 Study Site

Encino, California, 91316, United States
AFFIRM-1 Study Site

La Jolla, California, 92037, United States
AFFIRM-1 Study Site

Los Angeles, California, 90025, United States
AFFIRM-1 Study Site

Oceanside, California, 92056, United States
AFFIRM-1 Study Site

San Diego, California, 92103, United States
AFFIRM-1 Study Site

San Jose, California, 95124, United States
AFFIRM-1 Study Site

Sherman Oaks, California, 91403, United States
AFFIRM-1 Study Site

Temecula, California, 92591, United States
AFFIRM-1 Study Site

Jacksonville, Florida, 32256, United States
AFFIRM-1 Study Site

Lauderhill, Florida, 33319, United States
AFFIRM-1 Study Site

Miami Lakes, Florida, 33016, United States
AFFIRM-1 Study Site

Orlando, Florida, 32801, United States
AFFIRM-1 Study Site

Tampa, Florida, 33607, United States
AFFIRM-1 Study Site

Decatur, Georgia, 30030, United States
AFFIRM-1 Study Site

Boston, Massachusetts, 02114, United States
AFFIRM-1 Study Site

Boston, Massachusetts, 02131, United States
AFFIRM-1 Study Site

Princeton, New Jersey, 08540, United States
AFFIRM-1 Study Site

Brooklyn, New York, 11229, United States
AFFIRM-1 Study Site

Charlotte, North Carolina, 28211, United States
AFFIRM-1 Study Site

Media, Pennsylvania, 19063, United States
AFFIRM-1 Study Site

Austin, Texas, 78737, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.